Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01304524 · ClinicalTrials.gov registry record · Phase 2
A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
A Phase 2 study, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
NCT01304524 is a Phase 2 study that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 167 participants.
The verdict
NCT01304524, a Phase 2 study, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
Study Summary
This is randomized, placebo controlled study to determine safety and efficacy of VGX-3100 DNA Vaccine delivered by Electroporation to adult women with biopsy-proven HPV 16 or 18 associated Cervical intraepithelial neoplasia grade 2/3 or 3.
Interventions
- BIOLOGICAL Placebo
- DEVICE CELLECTRA™-5P
- BIOLOGICAL VGX 3100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2011-04 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01304524
The ClinicalTrials.gov registry entry for NCT01304524 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01304524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01304524 about?
NCT01304524 is a clinical study titled "A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3". This is randomized, placebo controlled study to determine safety and efficacy of VGX-3100 DNA Vaccine delivered by Electroporation to adult women with biopsy-proven HPV 16 or 18 associated Cervical intraepithelial neoplasia grade 2/3 or 3.
What is the current status of trial NCT01304524?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2011-04. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01304524?
The interventions under investigation include: Placebo (BIOLOGICAL), CELLECTRA™-5P (DEVICE), VGX 3100 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01304524?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.